Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 2
2010 4
2011 1
2012 4
2013 4
2014 4
2015 2
2016 3
2017 3
2018 1
2020 2
2021 2
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.
Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu GP, Latiri M, Davison EK, Ciufolini MA, Brémond P, Rebuffet E, Roche P, Derviaux C, Voisset E, Montersino C, Castellano R, Collette Y, Asnafi V, Betzi S, Dubreuil P, Combes S, Morelli X. Saez-Ayala M, et al. Among authors: betzi s. Nat Commun. 2023 May 29;14(1):3079. doi: 10.1038/s41467-023-38668-2. Nat Commun. 2023. PMID: 37248212 Free PMC article.
CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
Carrasco K, Montersino C, Derviaux C, Saez-Ayala M, Hoffer L, Restouin A, Castellano R, Casassa J, Roche P, Pasquier E, Combes S, Morelli X, Collette Y, Betzi S. Carrasco K, et al. Among authors: betzi s. J Med Chem. 2022 Apr 14;65(7):5660-5674. doi: 10.1021/acs.jmedchem.1c02168. Epub 2022 Mar 29. J Med Chem. 2022. PMID: 35348328 Free article.
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.
Calbert ML, Chandramouly G, Adams CM, Saez-Ayala M, Kent T, Tyagi M, Ayyadevara VSSA, Wang Y, Krais JJ, Gordon J, Atkins J, Toma MM, Betzi S, Boghossian AS, Rees MG, Ronan MM, Roth JA, Goldman AR, Gorman N, Mitra R, Childers WE, Graña X, Skorski T, Johnson N, Hurtz C, Morelli X, Eischen CM, Pomerantz RT. Calbert ML, et al. Among authors: betzi s. Mol Cancer Ther. 2023 Dec 8. doi: 10.1158/1535-7163.MCT-23-0487. Online ahead of print. Mol Cancer Ther. 2023. PMID: 38064712
PDZome-wide and structural characterization of the PDZ-binding motif of VANGL2.
Montserrat-Gomez M, Gogl G, Carrasco K, Betzi S, Durbesson F, Cousido-Siah A, Kostmann C, Essig DJ, Strømgaard K, Østergaard S, Morelli X, Trave G, Vincentelli R, Bailly E, Borg JP. Montserrat-Gomez M, et al. Among authors: betzi s. Biochim Biophys Acta Proteins Proteom. 2024 May 1;1872(3):140989. doi: 10.1016/j.bbapap.2023.140989. Epub 2023 Dec 23. Biochim Biophys Acta Proteins Proteom. 2024. PMID: 38142947
In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E. Ariey-Bonnet J, et al. Among authors: betzi s. Mol Oncol. 2020 Dec;14(12):3083-3099. doi: 10.1002/1878-0261.12810. Epub 2020 Oct 18. Mol Oncol. 2020. PMID: 33021050 Free PMC article.
40 results